Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer
But Has Ground To Make Up On Tecentriq
An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.
